Metabolon and Muses Labs Partner for Alzheimer’s Disease
Collaboration to Launch Joint Precision Medicine Studies, Bring New Clinical Trial Services to Market and Advance Care Protocols for Alzheimer’s Patients
RALEIGH, N.C. (Business Wire) July 13, 2016 – Muses Labs announced today it has partnered with Metabolon, Inc., the global leader in metabolomics, to study and apply metabolomics in individuals with pre- and early-symptomatic cognitive decline and Alzheimer’s disease. The companies expect to bring new clinical trial services and updated care protocols to the market in 2016.
Metabolomics is the study of small molecules called metabolites and is a powerful phenotyping technology for precision medicine. It measures changes in metabolite levels and maps them to the appropriate biochemical pathways to give clinicians a better understanding of health and the influences of genes, microbiome, diet, lifestyle and drug treatment.
“Muses Labs’ protocols utilize a patient’s genome, blood tests, medical history and lifestyle to direct care. Metabolomics adds additional significant insight into a patient’s biological status to improve identification of active pathologies and enable further refinement of patient care programs,” said Vik Chandra, CEO of Muses Labs. “Metabolomics has the potential to significantly expand the effectiveness of combination therapy protocols for Alzheimer’s and other complex diseases. Our collaboration with Metabolon has the power to advance precision medicine in this area.”
Muses Labs’ MEND™ Protocol is a data driven, technology enabled, personalized methodology to correctly identify and simultaneously treat the dozens of pathology drivers of age-related cognitive decline. It is designed to help patients who are beginning to have symptoms of age-related cognitive decline, those with a family history of dementia and patients with mild Alzheimer’s disease. The Protocol recommends optimal medical interventions personalized for each patient and has the potential to improve memory and cognitive function.
“We’re working together to expand the knowledge we can apply toward overcoming Alzheimer’s disease,” said John Ryals, PhD, CEO of Metabolon. “Our goal is to use our proprietary technology in conjunction with Muses Labs’ personalized Protocols to provide clinicians with a more accurate health assessment of patients experiencing cognitive decline as well as more actionable information. Metabolomics may help answer questions that surround complex, neurodegenerative diseases and refine personalized treatment.”
“While research into metabolomics and Alzheimer’s disease is in its early stages, we believe that by using this technology, the connections between metabolism and the underlying pathologies of Alzheimer’s disease will become better understood,” said Dr. Marwan Sabbagh, Research Professor of Neurology, University of Arizona College of Medicine, Chief Medical-Scientific Advisor, Muses Labs. “Metabolomics can guide the clinical care of Alzheimer’s disease today while laying the foundation for new interventions and protocols.”
Metabolon, Inc. is the world’s leading health technology company focused on the use of metabolomics in precision medicine. This powerful tool for assessing health is based on proprietary platforms and informatics that deliver biomarker discoveries, innovative diagnostic tests and ground-breaking partnerships in genomics-based health initiatives. Metabolon’s expertise is also accelerating research and product development across the pharmaceutical, biotechnology, consumer products, agriculture and nutrition industries, as well as academic and government organizations. Founded in 2000 and headquartered in Research Triangle Park, North Carolina, the company has conducted more than 5,000 independent and collaborative studies, resulting in over 550 peer-reviewed publications. For more information, please visit www.metabolon.com or follow us on LinkedIn or Twitter.
About Muses Labs
Muses Labs brings together 30 years of scientific research, hundreds of published clinical studies, and a team of highly-respected Alzheimer’s researchers, doctors and advanced technology. The company applies its clinical precision medicine platform and technology-enabled protocol to collect individual patient medical and behavioral data, identify underlying causes of age-related cognitive decline (such as Alzheimer’s disease and memory loss), and design personalized treatment plans. A comprehensive adherence program supports individuals and their caregivers to improve patient outcomes. This first personalized protocol is called the MENDTM Protocol (Metabolic Enhancement for NeuroDegeneration). For more information, visit www.museslabs.com.
Crossroads Public Relations and Marketing
Molly Thompson, Account Director
Vice President, Corporate Communications & Investor Relations